Metabolic Side Effects: Here We Go Again!
Daniel Carlat, MD
Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
Read More
Philip G. Janicak, M.D.
Professor of Psychiatry, Rush University Medical Center
Dr. Janicak has disclosed that he is a member of the speakers bureau of Abbott, Astra-Zeneca, Bristol-Myers Squibb, Janssen, and Pfizer, that he is a consultant for Astra-Zeneca, Bristol-Myers Squibb, Janssen, and Pfizer, and that he has received grant/research support from Astra-Zeneca, Bristol-Myers Squibb, Janssen, Neuronetics, and Sanofi-Synthelabo. Dr. Janicak has disclosed that propranolol has not been approved by the U.S. Food and Drug Administration for use in the treatment of agitation. Please consult product labeling for the approved usage.
Michael J. Gitlin, M.D.
Professor of Clinical Psychiatry, UCLA School of Medicine
Director of the Mood Disorders Clinic, UCLA Neuropsychiatric Hospital
Dr. Gitlin has disclosed that he is a member of the speakers bureau of Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, Astra Zeneca, and Janssen. Dr. Gitlin has disclosed that psychostimulants, modafinil, and T3 have not been approved by the U.S. Food and Drug Administration for use in the treatment of depression.
Please consult product labeling for the approved usages.Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.
© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.